drugset / Trial / NCT00454168
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission
RandomizedTreatment
Summary
RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, increase the number of white blood cells and platelets found in bone marrow or peripheral blood. Giving vaccine therapy together with GM-CSF may be an effective treatment for acute myeloid leukemia. It is not yet known whether giving vaccine therapy together with GM-CSF is more effective than giving placebo together with GM-CSF in treating acute myeloid leukemia. PURPOSE: This randomized phase III trial is studying vaccine therapy and GM-CSF to see how well they work compared with a placebo and GM-CSF in treating patients with acute myeloid leukemia in remission.
Timeline
- Start
- 2005-05
- Primary completion
- 2009-04
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PR1 leukemia peptide vaccine | Vaccine | — | Subcutaneous |
| Background | sargramostim | Protein / enzyme biologic | — | Subcutaneous |